Cargando…

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells

Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Natarajan, Gayathri, Oghumu, Steve, Terrazas, Cesar, Varikuti, Sanjay, Byrd, John C., Satoskar, Abhay R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938315/ https://www.ncbi.nlm.nih.gov/pubmed/27471620 http://dx.doi.org/10.1080/2162402X.2016.1151592

Ejemplares similares

Ly6C(hi) inflammatory monocytes promote susceptibility to Leishmania donovani infection
por: Terrazas, Cesar, et al.
Publicado: (2017)

Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells
por: Varikuti, Sanjay, et al.
Publicado: (2020)

The emerging role of dendritic cells in the host immune response against Helicobacter pylori
por: Oghumu, Steve, et al.
Publicado: (2014)

Severe B Cell Deficiency in Mice Lacking the Tec Kinase Family Members Tec and Btk
por: Ellmeier, Wilfried, et al.
Publicado: (2000)

Multilocus microsatellite signature and identification of specific molecular markers for Leishmania aethiopica
por: Kebede, Nigatu, et al.
Publicado: (2013)

Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC
por: Anderson, Kelvin, et al.
Publicado: (2020)

The IL-33/ST2 Axis in Immune Responses Against Parasitic Disease: Potential Therapeutic Applications
por: Ryan, Nathan, et al.
Publicado: (2020)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Leishmania donovani Infection Induces Anemia in Hamsters by Differentially Altering Erythropoiesis in Bone Marrow and Spleen
por: Lafuse, William P., et al.
Publicado: (2013)

PI3K-γ inhibitors in the therapeutic intervention of diseases caused by obligate intracellular pathogens
por: Oghumu, Steve, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function
por: Trory, Justin S., et al.
Publicado: (2022)

STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade
por: Varikuti, Sanjay, et al.
Publicado: (2017)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Deficiency of p110δ Isoform of the Phosphoinositide 3 Kinase Leads to Enhanced Resistance to Leishmania donovani
por: Khadem, Forough, et al.
Publicado: (2014)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
por: Liu, Jia, et al.
Publicado: (2022)

Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time
por: Duan, Rundan, et al.
Publicado: (2021)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
por: Wei, Li, et al.
Publicado: (2016)

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
por: Li, Ling, et al.
Publicado: (2023)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity
por: Toenjes, Sean T., et al.
Publicado: (2023)

Pediatric Cutaneous Leishmaniasis in an Endemic Region in Turkey: A Retrospective Analysis of 8786 Cases during 1998-2014
por: Aksoy, Mustafa, et al.
Publicado: (2016)

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
por: Colado, Ana, et al.
Publicado: (2018)

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
por: Treon, Steven P., et al.
Publicado: (2020)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2019)

Role of Co-stimulation in Leishmaniasis
por: Tuladhar, Rashmi, et al.
Publicado: (2011)

Foxa1 and Foxa2 in thymic epithelial cells (TEC) regulate medullary TEC and regulatory T-cell maturation
por: Lau, Ching-In, et al.
Publicado: (2018)

Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases
por: Volpedo, Greta, et al.
Publicado: (2019)

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice
por: Schutt, Steven D., et al.
Publicado: (2015)

Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway
por: Zhu, Jin-Feng, et al.
Publicado: (2023)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
por: Guo, Ailin, et al.
Publicado: (2015)

Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice
por: Rao, Huanan, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

TEC Installation
por: CERN. Geneva. Audiovisual Unit
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_k8pa58fple37hrjcs51kroh9q0